BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:For decades\, RAS has existed as an elusive therapeutic target
 \, and drugging this high-value oncogene was deemed impossible. Despite t
 his\, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated th
 at RAS is in fact druggable and that drugging this protein unlocks a worl
 d of successful therapeutic interventions. Now\, the future looks bright 
 for treating patients with cancers harboring the RAS mutation.\n\nThe 4th
  RAS-Targeted Drug Development Summit returns as the definitive industry 
 dedicated forum for the whole community of individuals committed to targe
 ting RAS. Bigger and better than ever before\, we will unite 300+ experts
  to showcase 3-days of exclusive\, never shared before data as we delve i
 nto accelerating discovery and emerging strategies\, optimizing translati
 on and pre-clinical development\, and advancing the landscape of clinical
  trials for combinations and monotherapies.\n\nWith mounting success in t
 argeted RAS drugs\, leading frontiers and experts must unite and continue
  accelerating the applications of this therapeutic for patients in need. 
 Through novel data\, expert insight\, and exclusive discussions with glob
 al leaders\, we will facilitate vital learnings to progress RAS therapeut
 ics to drug all-mutations from G12C\, G12D\, and G12V. Continuing to adva
 nce valuable combination therapies into the clinic\, and finally\, crack 
 resistance to RAS targeted therapeutics.\n\nThis year’s forum returns as 
 the only industry-focused event wholly dedicated to RAS-mutant cancers. W
 ith this\, we will be uniting all experts from across the globe to spend 
 3 days in Boston\, learning\, discussing\, and progressing anti-RAS thera
 pies to the patient.\n
DTEND:20220928T180000
DTSTAMP:20260512T232943Z
DTSTART:20220926T083000
LOCATION:Boston Marriott Burlington\, One Burlington Mall Road\, Burlingto
 n\, Massachusetts\, 01803\,
SEQUENCE:0
SUMMARY:For decades\, RAS has existed as an elusive therapeutic target\, a
 nd drugging this high-value oncogene was deemed impossible. Despite this\
 , the first...
UID:e30fd798-f2ab-4f1b-8f6e-08c0c3626f25
END:VEVENT
END:VCALENDAR